Eurobio Scientific Presents Data on Breast Cancer Treatment Decisions at ESMO 2022

Eurobio Scientific collaborated with Myriad Genetics at the European Society for Medical Oncology (ESMO) Congress 2022 to present new insights into personalized breast cancer treatment. An industry satellite symposium focused on how genetic signatures can inform chemotherapy decisions for premenopausal patients with ER+/HER2- early breast cancer.

Dr. Anastasia Constantinidou presented key data from ESMO 2022. The findings demonstrated how the EndoPredict test can assist clinicians in guiding treatment choices and potentially avoiding overtreatment for this patient group. The presented data emphasized the role of molecular diagnostics in therapeutic strategy.

The symposium aimed to educate healthcare professionals on utilizing genomic information for more precise patient care. Eurobio Scientific, a company involved in diagnostic solutions, seeks to advance medical knowledge and improve patient outcomes through such scientific exchanges.

ESMO is a major international congress for oncologists and researchers. The industry symposia held alongside the main congress provide a platform for companies to share relevant scientific findings and engage with the medical community on advancements in cancer care.